Advancing Inclusive Research

Clinical trials offer people with serious and life-threatening diseases a chance to receive investigational medicines that have the potential to improve outcomes. At Genentech, we are deeply committed to addressing barriers to clinical trial participation and advancing inclusive research.

Read our full position statement here.

Our Vision: The Future of Healthcare is Within All of Us

The genetic data available today does not reflect the majority of our diverse global population. In order for us to deepen our understanding of disease and develop more personalized treatments, we must have more complete information and study a broader population, including underrepresented racial and ethnic minorities.

Clinical and genetic data enriched by including more representative patient populations will enable us to evolve the promise of personalized healthcare to achieve more accurate diagnoses, improve access to therapies, and optimize treatment outcomes for all patients.

Genentech Taking Action

Genentech is committed to advancing the following priorities:

Recruit More Representative Populations into Clinical Research

  • Conducting pilots in three clinical studies in the U.S. to understand best practices in study screening and recruitment
  • Reexamining study site selection

Enhancing Personalized Health Care

  • Advancing knowledge of clinical outcomes in patients across race/ethnicity and gender by leveraging Genentech’s unique portfolio and data assets
  • Developing new approaches for supporting populations currently understudied in genomic and clinical research

Purpose-Driven Partnerships

  • Collaborating with our External Council for Inclusive Research to establish new standards and principles for inclusive research at Genentech
  • Building a roadmap for engaging diverse populations in all phases of clinical research

Advancing Inclusive Research: Full Position Statement

Clinical trials offer people with serious and life-threatening diseases a chance to receive investigational medicines that have the potential to improve outcomes. At Roche and Genentech, we are deeply committed to addressing barriers to clinical trial participation and advancing inclusive research.

Approximately half of the U.S. population is projected to be non-Caucasian by 2045. We believe more needs to be done to ensure clinical trial participants are more representative of the broader patient population. Today, fewer than 10 percent of U.S. patients participate in clinical trials and of those only 5-15 percent are non-Caucasian.

The health care industry as a whole has the opportunity to shine a spotlight on disparities and address barriers to clinical access. To deliver on the promise of personalized health care, we must consider differences across all populations.

Roche and Genentech are working to ensure clinical trials are conducted with representative populations of participants. By partnering with stakeholders, we can collectively combine scientific advances, new technologies and real-world data to drive scientific innovation and create new standards for inclusive clinical research.